51091 Deucravacitinib, an oral, selective, allosteric tyrosi…
Emerging
0
Citations0
Refs2024
Year
Search Works
Work Details
- DOI 10.1016/j.jaad.2024.07.133
- OpenAlex ID W4402104102
- Type Article
- Language EN
- Published 01 Sep 2024
- Volume 91 (3)
- Pages AB31
- Source Journal of the American Academy of Derma…
- Publisher Elsevier BV
- Countries 2
- Institutions 6
- Added 01 Sep 2024
- Updated 28 Oct 2026
External Links
MENU
0
51091 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials
Article 2024 EN Bronze
0
Citations
0
References
11
Authors
0.00
FWCI
Topics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
11 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Linda Stein Gold | Henry Ford Health (US) | |
| 2 | Subhashis Banerjee | Bristol-Myers Squibb (United S… (US) | |
| 3 | Matthew J. Colombo | Bristol-Myers Squibb (United S… (US) | |
| 4 | Renata M. Kisa | Bristol-Myers Squibb (United S… (US) | — |
| 5 | Victoria Berger | Bristol-Myers Squibb (United S… (US) | — |
| 6 | Kim Hoyt | Bristol-Myers Squibb (United S… (US) | — |
| 7 | Jennifer Soung | — | |
| 8 | Tiago Ribeiro Torres | Universidade do Porto (PT) Centro Hospitalar do Porto (PT) | |
| 9 | Neal D Bhatia | Therapeutics Clinical Research (US) | |
| 10 | Brad P. Glick | — | — |
| 11 | Mark D. Kaufmann | Icahn School of Medicine at Mo… (US) | — |
Related Works
10Data: OpenAlex